Sneddon-wilkinson disease induced by sorafenib in a patient with advanced hepatocellular carcinoma

Internal Medicine

Volumn 54, Issue 6, 2015, Pages 597-600

  Tajiri, Kazuto ^a   Nakajima, Takahiko ^a   Kawai, Kengo ^a   Minemura, Masami ^a   Sugiyama, Toshiro ^a  

^a TOYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Advanced HCC; Sneddon Wilkinson disease; Sorafenib; Subcorneal pustular dermatosis

Indexed keywords

CISPLATIN; FLUOROURACIL; LACTATE DEHYDROGENASE; SORAFENIB; STEROID; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CASE REPORT; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HUMAN; HUMAN TISSUE; JAPANESE (PEOPLE); LIVER CELL CARCINOMA; MALE; NEUTROPHIL CHEMOTAXIS; SKIN BIOPSY; STEROID THERAPY; SUBCORNEAL PUSTULAR DERMATOSIS; ANALOGS AND DERIVATIVES; BULLOUS SKIN DISEASE; CARCINOMA, HEPATOCELLULAR; CHEMICALLY INDUCED; LIVER NEOPLASMS; PATHOLOGY;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MALE; NIACINAMIDE; PHENYLUREA COMPOUNDS; SKIN DISEASES, VESICULOBULLOUS;

EID: 84924853792     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.54.3675     Document Type: Article

References (24)

1. Finn RS. Drug therapy: sorafenib. Hepatology 51: 1843-1849, 2010.
2. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
3. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sora-fenib in patients in the Asia-Pacific region with advanced hepato-cellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
4. Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 161: 1045-1051, 2009.
5. McLellan B, Kerr H. Cutaneous toxicities of the multikinase in-hibitors sorafenib and sunitinib. Dermatol Ther 24: 396-400, 2011.
6. Cheng S, Edmonds E, Ben-Gashir M, Yu RC. Subcorneal pustular dermatosis: 50 years on. Clin Exp Dermatol 33: 229-233, 2008.
7. Atukorala DN, Joshi RK, Abanmi A, Jeha MT. Subcorneal pustu-lar dermatosis and IgA myeloma. Dermatology 187: 124-126, 1993.
8. Lautenschlager S, Itin PH, Hirsbrunner P, Buchner SA. Subcorneal pustular dermatosis at the injection site of recombinant human granulocyte-macrophage colony-stimulating factor in a patient with IgA myeloma. J Am Acad Dermatol 30: 787-789, 1994.
9. Butt A, Burge SM. Sneddon-Wilkinson disease in association with rheumatoid arthritis. Br J Dermatol 132: 313-315, 1995.
10. Iobst W, Ingraham K. Sneddon-Wilkinson disease in a patient with rheumatoid arthritis. Arthritis Rheum 52: 3771, 2005.
11. Delaporte E, Colombel JF, Nguyen-Mailfer C, Piette F, Cortot A, Bergoend H. Subcorneal pustular dermatosis in a patient with Crohn’s disease. Acta Derm Venereol 72: 301-302, 1992.
12. Tsuruta D, Matsumura-Oura A, Ishii M. Subcorneal pustular der-matosis and Sjögren’s syndrome. Int J Dermatol 44: 955-957, 2005.
13. Buchet S, Humbert P,Blanc D, et al. [Subcorneal pustular derma-tosis associated with epidermoid carcinoma of the lung]. Ann Der-matol Venereol 118: 125-128, 1991 (in French).
14. Villey MC, Ehrsam E, Marrakchi S, Colombel JF, Thomas P. Apu-doma and subcorneal pustular dermatosis (Sneddon-Wilkinson dis-ease). Dermatology 185: 269-271, 1992.
15. Kasha EE, Epinette WW. Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) in association with a monoclonal.
16. IgA gammopathy: a report and review of the literature. J Am Acad Dermatol 19: 854-858, 1988.
17. Agarwal A, Shivaswamy KN, Raja B, Thappa DM, Verma SK. Subcorneal pustlar dermatosis and thymoma: an association or co-incidence? Indian J Dermatol 51: 272-274, 2006.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Or-ganization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
19. Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 37: 755-762, 2007.
20. Sneddon IB, Wilkinson DS. Subcorneal pustular dermatosis. Br J Dermatol 68: 385-394, 1956.
21. Grob JJ, Mege JL, Capo C, et al. Role of tumor necrosis factor-alpha in Sneddon-Wilkinson subcorneal pustular dermatosis. A model of neutrophil priming in vivo. J Am Acad Dermatol 25: 944-947, 1991.
22. Takematsu H, Tagami H. Quantification of chemotactic peptides (C5a anaphylatoxin and IL-8) in psoriatic lesional skin. Arch Der-matol 129: 74-80, 1993.
23. Maki N, Komine M, Takatsuka Y, Maekawa T, Murata S, Ohtsuki M. Pustular eruption induced by sorafenib in a case of psoriasis vulgaris. J Dermatol 40: 299-300, 2013.
24. Jain L, Gardner ER, Figg WD, Chernick MS, Kong HH. Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction. Pharmacotherapy 30: 52-56, 2010.